{"id":49425,"date":"2022-10-10T15:02:41","date_gmt":"2022-10-10T13:02:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/"},"modified":"2022-10-10T15:02:41","modified_gmt":"2022-10-10T13:02:41","slug":"atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/","title":{"rendered":"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance"},"content":{"rendered":"
\n

\nTotal revenue of $89 to $90 million<\/i>\n<\/p>\n

\nTotal revenue growth of 42% to 43%, including organic revenue growth of 51% to 53%<\/i>\n<\/p>\n

\nFull-year 2022 total revenue growth now expected to approximate 40%<\/i>\n<\/p>\n

CARLSBAD, Calif.–(BUSINESS WIRE)–Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today select preliminary financial results for the third quarter ended September 30, 2022, and updated full-year 2022 revenue guidance ahead of investor meetings scheduled during the 2022 North American Spine Society (NASS) Annual Meeting<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nPreliminary Third Quarter 2022 Revenue Ranges<\/b>\n<\/p>\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nQuarter Ended September 30, 2022\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOrganic Revenue\n<\/p>\n<\/td>\n

\n

\n$78.0M to $78.8M\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEOS-Related Revenue\n<\/p>\n<\/td>\n

\n

\n$11.0M to $11.2M\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Revenue\n<\/p>\n<\/td>\n

\n

\n$89.0M to $90.0M\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nPreliminary, third quarter 2022 total revenue is expected to grow 42% to 43% compared to third quarter 2021. Propelled by continued strong momentum of the PTP\u2122 approach, procedural volume growth exceeded 30% and drove organic revenue growth of 51% to 53%. The Company closed the third quarter with a cash balance of approximately $106 million.\n<\/p>\n

\nThe Company now expects full year 2022 revenue growth to approximate 40% compared to the 34% growth expectation provided in previous guidance.\n<\/p>\n

\nThe select preliminary financial results announced today are based on the Company\u2019s current expectations and may be adjusted as a result of, among other things, completion of customary quarter-end close review procedures and further financial review.\n<\/p>\n

\nDate and Access Details for Third Quarter Financial Results<\/b>\n<\/p>\n

\nThe Company expects to announce third quarter 2022 financial and operating results on November 3, 2022, after the market close. The Company will host a live webcast that day at 1:30 p.m. PT \/ 4:30 p.m. ET.\n<\/p>\n

\nWebcast<\/b>\n<\/p>\n

\nTo access the live webcast, please visit the Investor Relations Section<\/a> of ATEC\u2019s Corporate Website.\n<\/p>\n

\nDial-in<\/b>\n<\/p>\n

\nTo dial into the live webcast, please register at this link<\/a>. Access details will be shared via email.\n<\/p>\n

\nReplay<\/b>\n<\/p>\n

\nA replay of the webcast will remain available through the Investor Relations Section<\/a> of ATEC\u2019s Corporate Website for twelve months. In addition, a dial-in replay will be available beginning two hours after the webcast\u2019s completion through November 10, 2022. Access the replay by dialing (800) 770-2030 and referencing conference ID number 97241.\n<\/p>\n

\nAbout ATEC<\/b>\n<\/p>\n

\nATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC\u2019s Organic Innovation Machine\u2122 is focused on developing new approaches that integrate seamlessly with the Company\u2019s expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC\u2019s vision is to become the Standard Bearer in Spine. For more information, visit us at www.atecspine.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described therein. Forward-looking statements include references to the Company\u2019s expectations with respect to future revenue and growth. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products in the Company\u2019s pipeline; failure to achieve acceptance of the Company\u2019s products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third-party reimbursement for procedures performed using the Company\u2019s products; the Company\u2019s ability to compete with other products and emerging new technologies; product liability exposure; patent infringement claims; and changes to our financial results for the quarter ended September 30, 2022 due to the completion of financial closing procedures. The words \u201cbelieve,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201clook forward\u201d and \u201canticipate,\u201d and variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company’s most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor\/Media Contact:<\/b>
Tina Jacobsen, CFA
\n
Investor Relations
\n
(760) 494-6790
\n
investorrelations@atecspine.com<\/a>\n<\/p>\n

\nCompany Contact:<\/b>
J. Todd Koning
\n
Chief Financial Officer
\n
Alphatec Holdings, Inc.
\n
investorrelations@atecspine.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Total revenue of $89 to $90 million Total revenue growth of 42% to 43%, including organic revenue growth of 51% to 53% Full-year 2022 total revenue growth now expected to approximate 40% CARLSBAD, Calif.–(BUSINESS WIRE)–Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today select … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49425","6":"format-standard","7":"category-industry"},"yoast_head":"\nATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Total revenue of $89 to $90 million Total revenue growth of 42% to 43%, including organic revenue growth of 51% to 53% Full-year 2022 total revenue growth now expected to approximate 40% CARLSBAD, Calif.–(BUSINESS WIRE)–Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today select ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-10T13:02:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221010005157\/en\/1596201\/21\/informed_logo_on_white.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance\",\"datePublished\":\"2022-10-10T13:02:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/\"},\"wordCount\":763,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005157\\\/en\\\/1596201\\\/21\\\/informed_logo_on_white.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/\",\"name\":\"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005157\\\/en\\\/1596201\\\/21\\\/informed_logo_on_white.jpg\",\"datePublished\":\"2022-10-10T13:02:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005157\\\/en\\\/1596201\\\/21\\\/informed_logo_on_white.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005157\\\/en\\\/1596201\\\/21\\\/informed_logo_on_white.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/","og_locale":"en_US","og_type":"article","og_title":"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance - Pharma Trend","og_description":"Total revenue of $89 to $90 million Total revenue growth of 42% to 43%, including organic revenue growth of 51% to 53% Full-year 2022 total revenue growth now expected to approximate 40% CARLSBAD, Calif.–(BUSINESS WIRE)–Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today select ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-10T13:02:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221010005157\/en\/1596201\/21\/informed_logo_on_white.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance","datePublished":"2022-10-10T13:02:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/"},"wordCount":763,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005157\/en\/1596201\/21\/informed_logo_on_white.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/","url":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/","name":"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005157\/en\/1596201\/21\/informed_logo_on_white.jpg","datePublished":"2022-10-10T13:02:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221010005157\/en\/1596201\/21\/informed_logo_on_white.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221010005157\/en\/1596201\/21\/informed_logo_on_white.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/atec-announces-select-preliminary-third-quarter-2022-financial-results-and-raises-guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ATEC Announces Select Preliminary Third Quarter 2022 Financial Results and Raises Guidance"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49425"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49425\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}